Recombinant Mouse TFF1 (C-6His)

SKU: EPT100

Size:50ug

Description:Recombinant Mouse Trefoil Factor 1 is produced by our Mammalian expression system and the target gene encoding Gln22-Phe87 is expressed with a 6His tag at the C-terminus.

Accession:Q08423

Molecular weight:8.3 KDa

Apparent molecular weight:15 KDa, reducing conditions

Other names:Trefoil factor 1; Protein pS2; Tff1; Bcei; Ps2

Storage condition:Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Purity:Greater than 95% as determined by reducing SDS-PAGE.

Endotoxin:Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.

Biological activity:

Redissolve:Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Storage:Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Delivery condition:The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.

Background:Trefoil Factor 1 (TFF1) belongs to the three structurally related secreted proteins that contain trefoil domains.TFF1 is an approximately peptide that has an important effect in epithelial regeneration and wound healing.It originates from musculus and highly expressed by goblet cells of the gastric and intestinal mucosa and by conjunctival goblet cells. TFF1 is a copper-binding protein that can form disulfide-linked homodimers, associate into disulfide-linked complexes with Gastrokine 2, and form non-covalent complexes with the mucin MUC5AC. TFF1 is down-regulated during the progression from gastritis to gastric dysplasia to gastric cancer, although it is up-regulated in breast and prostate cancers. TFF1 inhibits the formation of calcium oxalate crystals, and its excretion in the urine is reduced in patients with kidney stones.